Rasonque, manufactured by Revolution Medicines in California, is an inhibitor for the most common type of pancreatic cancer. The tablet, which is taken once daily, targets multiple forms of a protein called RAS that drives tumor growth.

In a press release, the FDA called Rasonque a “new treatment option for patients with advanced pancreatic cancer,” noting the agency approved it more than six months ahead of its review deadline.

CANCER TREATMENT DELAYS SURGE ACROSS US AS DOCTOR WARNS SYSTEM ‘NEEDS FIXING IMMEDIATELY’

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” acting FDA Commissioner Kyle Diamantas said in a press release.

“I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality.”

The authorization is for adults with metastatic pancreatic cancer that either did not respond to at least one prior treatment or could not receive certain combination drug therapies.

Pancreatic adenocarcinoma remains one of the deadliest forms of oncology in the U.S., accounting for up to 95% of the roughly 67,000 annual pancreatic cancer cases identified by the National Cancer Institute.

PATIENTS REMAIN CANCER-FREE NEARLY 3 YEARS AFTER RECEIVING EXPERIMENTAL IMMUNOTHERAPY

While the disease makes up only 3.2% of total cancer diagnoses, it causes a disproportionately high number of cancer deaths because it is often found late and can spread quickly.

The new drug was approved after a randomized, open-label trial of 500 patients with pre-treated metastatic disease. Patients taking Rasonque achieved a median overall survival of 13.2 months, nearly double the 6.7-month survival rate seen in the standard chemotherapy control group.

“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.

CLICK HERE FOR MORE HEALTH STORIES

Regulators accelerated the medication’s path to market by granting it priority review, orphan drug status and a breakthrough therapy designation.

Additionally, the filing was evaluated using the FDA commissioner’s National Priority Voucher pilot program to speed up access to critical public health treatments.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Ahead of the official green light, the agency issued a “safe to proceed” letter in May, opening an expanded access protocol that allowed patients to receive the drug before final approval.

Safety profiles show that the most frequent adverse events linked to Rasonque included rash, diarrhea, mouth sores (stomatitis), nausea, fatigue, vomiting, abdominal pain, fluid retention (edema), reduced appetite and bleeding (hemorrhage).

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“Today’s landmark approval is the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease,” said Anna Berkenblit, M.D., chief scientific and medical officer of the Pancreatic Cancer Action Network (PanCAN).

“I believe this drug will transform how pancreatic cancer is treated, giving people the opportunity for more time with loved ones, the possibility of a better quality of life and optimism that continued research may lead to even greater advances.”

Qatar’s government requested to buy up to four KC-46As, eight PW4062 turbofan engines, 10 AN/ALR-69A radar warning receivers, 15 Guardian Laser Transmitter Assemblies for Large Aircraft Infrared Countermeasure systems and 8 LAIRCM system processor replacements, according to a Thursday release.

The proposed sale also includes “non-major defense equipment,” such as precision navigation, transportation and airlift support, personnel training and training equipment and other related logistical and program support items, per the statement.

“The proposed sale will increase Qatar’s capability to meet current and future threats by enhancing its defense capabilities and interoperability with U.S. and allied forces and reinforcing Qatar’s strategic role in regional security,” the release reads.

The potential sale is meant to support U.S. foreign policy and national security objectives through assisting in Qatar’s security. The U.S. government statement describes the country as a “strategic regional partner” that continues to be an “important force” for political stability and economic progress in the Middle East.

Principal contractors for the envisioned deal include Boeing, Pratt & Whitney Military Engines, RTX Corporation and Northrop Grumman Corporation.

The proposed sale’s implementation will not require any additional U.S. government or contractor representatives to Qatar, the announcement says.

“At this time, the U.S. Government is not aware of any offset agreement proposed in connection with this potential sale,” the statement says. “Any offset agreement will be defined in negotiations between the purchaser and the contractor.”

The KC-46A provides aerial refueling support to the U.S. Air Force, Navy, Marine Corps and partner nations and has greater refueling, cargo and aeromedical evacuation capabilities than the aging KC-135s.

The announcement comes as questions persist surrounding the security features of a Qatari-donated Air Force One aircraft that has been modified for U.S. presidential use. President Donald Trump began using the new jet in July and has since announced it will be “maxed out” for upgrades.

Qatar’s government requested to buy up to four KC-46As, eight PW4062 turbofan engines, 10 AN/ALR-69A radar warning receivers, 15 Guardian Laser Transmitter Assemblies for Large Aircraft Infrared Countermeasure systems and 8 LAIRCM system processor replacements, according to a Thursday release.

The proposed sale also includes “non-major defense equipment,” such as precision navigation, transportation and airlift support, personnel training and training equipment and other related logistical and program support items, per the statement.

“The proposed sale will increase Qatar’s capability to meet current and future threats by enhancing its defense capabilities and interoperability with U.S. and allied forces and reinforcing Qatar’s strategic role in regional security,” the release reads.

The potential sale is meant to support U.S. foreign policy and national security objectives through assisting in Qatar’s security. The U.S. government statement describes the country as a “strategic regional partner” that continues to be an “important force” for political stability and economic progress in the Middle East.

Principal contractors for the envisioned deal include Boeing, Pratt & Whitney Military Engines, RTX Corporation and Northrop Grumman Corporation.

The proposed sale’s implementation will not require any additional U.S. government or contractor representatives to Qatar, the announcement says.

“At this time, the U.S. Government is not aware of any offset agreement proposed in connection with this potential sale,” the statement says. “Any offset agreement will be defined in negotiations between the purchaser and the contractor.”

The KC-46A provides aerial refueling support to the U.S. Air Force, Navy, Marine Corps and partner nations and has greater refueling, cargo and aeromedical evacuation capabilities than the aging KC-135s.

The announcement comes as questions persist surrounding the security features of a Qatari-donated Air Force One aircraft that has been modified for U.S. presidential use. President Donald Trump began using the new jet in July and has since announced it will be “maxed out” for upgrades.

But on July 15, the U.S. House of Representatives passed a bill that includes $500 million in Foreign Military Financing for Taiwan, one in a chain of Pacific Rim allies that U.S. officials have long seen as a buffer against Chinese military expansion.

While the half-billion-dollar allocation in the 2027 fiscal year appropriations bill does not commit money to a particular arms package, analysts say it’s a sign that the Republican Party-dominated Congress values the defense of Taiwan in case China ever attacks with its larger armed forces, and that Washington intends to fulfill at least older arms purchase deals.

“This $500 million Foreign Military Funding demonstrates that Congress has not reduced its security support for Taiwan following the Trump-Xi meeting and reflects Congress’s desire to avoid long-term constraints on military aid to Taiwan due to White House negotiations with China through appropriations and delivery requirements,” said Huang Chung-ting, associate research fellow with the Institute for National Defense and Security Research in Taipei.

The US usually sells weapons to Taiwan – with drones, expect the reverse

Trump’s signature, needed to pass the appropriations bill, would imply continued weapons sales of some kind despite the unknown fate of the $14 billion package, analysts said.

Foreign Military Financing – usually grants or loans – for U.S. allies abroad may technically go toward acquiring weapons, military training or other related services.

“Foreign military financing concerns how weapons are ultimately paid for but not whether the weapons are actually sold or transferred in the first place,” said Sean King, vice president of New York-based political consultancy Park Strategies.

Trump has not ostensibly withdrawn any previous but unfulfilled U.S. arms sales for Taiwan, meaning that the proposed congressional funding could go toward one of those, experts say. U.S. arms sales to Taiwan date back more than four decades and can take years before payments and delivery dates are settled. As of April, sales of 30 individual weapon types were partly unfulfilled, according to the Taiwan Security Monitor research initiative of the George Mason University’s Schar School of Policy and Government.

The most recent items appear in a $11.1 billion batch of weaponry fully approved by Washington in December. It includes M109A7 self-propelled howitzers, the high mobility artillery rocket system HIMARS, Javelin anti-tank missiles and unmanned attack aircraft systems. Taiwan’s Cabinet approved its own special budget in May to help pay for the purchases.

“My assessment is that while there was indeed a political pause after the Trump-Xi meeting, it was not a complete halt to arms sales to Taiwan, but rather (it) targeted new cases that had not yet received approval,” Huang said.

“This delay likely involved Trump’s negotiations with China, a review of weapons stockpiles and internal White House scrutiny, and cannot be explained by a single reason,” he said.

The appropriations bill still requires U.S. Senate review before it would go to Trump’s office.

China claims sovereignty over self-ruled Taiwan and has threatened to take the island by force, if needed. Over the past four years the People’s Liberation Army has increased the frequency of military exercises near Taiwan, often in the 160km (100 miles) strait separating them.

Trump said after his meeting with the Chinese president that withholding the arms deal was a “good negotiating chip.” But in June, the U.S. State Department reiterated long-standing policy that arms sales to Taiwan were not dependent on Beijing’s consent.

Experts anticipate a White House announcement on the $14 billion arms package only after Trump and Xi meet in September in the United States, as announced by Washington.

“It may be that Trump is delaying a public announcement until after Xi’s visit to avoid being the skunk who came to the garden party,” said Doug Barry, a professor at The George Washington University and a former communications director with the U.S.-China Business Council.

“It’s odd there has been no public announcement,” he said.